- Report Quarter 4
- Report Quarter 4
- Report Quarter 4
- Report Quarter 4
- Report Quarter 4
- Report Quarter 4
- Report Quarter 4
- Report Quarter 4
- Report Quarter 4
- Report Quarter 4
| ART | |
| Pre-ART | |
| Isonazid Prevention Therapy (IPT) | |
| STI | |
| VCCT | |
| Expose Infant |
| ART | |
| Pre-ART | |
| Isonazid Prevention Therapy (IPT) | |
| Home Based Care | |
| STI | |
| VCCT | |
| Linked Response |
| ART | |
| Pre-ART | |
| Isonazid Prevention Therapy (IPT) | |
| Home Based Care | |
| STI | |
| VCCT | |
| Linked Response | |
| Expose Infant |
| ART | |
| Pre-ART | |
| Isonazid Prevention Therapy (IPT) | |
| Home Based Care | |
| STI | |
| VCCT | |
| Linked Response | |
| Expose Infant | |
| Percentage of adults with HIV known to be on treatment 12,24,60 months after initiation of antiretroviral therapy |
| Report HIV/AIDS Treatment and HCV-HIV Co-infection | |
| Report B-IACM | |
| Report Boosted CoPCT for Key Populations | |
| Report STI |
| Summary HIV/AIDS and HCV-HIV Co-infection | |
| Detail HIV/AIDS and HCV-HIV Co-infection (Path 1) | |
| Detail HIV/AIDS and HCV-HIV Co-infection (Path 2) | |
| HCV-HIV Co-Infection | |
| Expose Infant | |
| VCCT Report | |
| STI Report |
| Summary HIV/AIDS and HCV-HIV Co-infection | |
| Report Detail HIV/AIDS and HCV-HIV Co-infection (Path 1) | |
| Report Detail HIV/AIDS and HCV-HIV Co-infection (Path 2) | |
| Report Positive Prevention, TB-HIV and Pregnance Women | |
| Report HCV-HIV Co-Infection | |
| Report on Partner Notification Tracing and Testing (PNTT) | |
| Report B-IACM | |
| Report Expose Infant | |
| Report VCCT | |
| Report STI |
| Art | |
| Pre Art | |
| Isonazid Prevention Therapy (IPT) | |
| Expose Infant | |
| VCCT | |
| STI |
| ART | |
| Pre-ART | |
| Isonazid Prevention Therapy (IPT) | |
| VCCT | |
| STI | |
| Expose Infant |
| ART | |
| Pre-ART | |
| Isonazid Prevention Therapy (IPT) | |
| VCCT | |
| STI | |
| Expose Infant |
